Circadian Rhythm Sleep Disorders

2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

VP
Vanda PharmaceuticalsWASHINGTON, DC
2 programs
1
1
VEC-162Phase 21 trial
tasimelteonPhase 11 trial
Active Trials
NCT02776215Completed24Est. Dec 2017
NCT00490945Completed45Est. Mar 2005

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Vanda PharmaceuticalsVEC-162
Vanda Pharmaceuticalstasimelteon

Clinical Trials (2)

Total enrollment: 69 patients across 2 trials

Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult Volunteers

Start: Jul 2004Est. completion: Mar 200545 patients
Phase 2Completed

Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents

Start: Oct 2016Est. completion: Dec 201724 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space